Up to one-third of patients with ulcerative colitis (UC) do not respond to standard medications, including mesalamine, steroids and thiopurines. The recognition that UC-related pathological process is the result of an altered balance between inflammatory and counter-regulatory signals, mostly mediated by cytokines, has led to the development of novel compounds, which are now ready to move into clinical practice. This article summarizes the recent data on the development and use of compounds either inhibiting inflammatory cytokines or enhancing the activity of counter-regulatory cytokines in patients with UC and murine models of UC.
Monteleone, G., Pallone, F., Caprioli, F. (2013). Investigational cytokine-targeted therapies for ulcerative colitis. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 22(9), 1123-1132 [10.1517/13543784.2013.813931].
Investigational cytokine-targeted therapies for ulcerative colitis
MONTELEONE, GIOVANNI;PALLONE, FRANCESCO;
2013-09-01
Abstract
Up to one-third of patients with ulcerative colitis (UC) do not respond to standard medications, including mesalamine, steroids and thiopurines. The recognition that UC-related pathological process is the result of an altered balance between inflammatory and counter-regulatory signals, mostly mediated by cytokines, has led to the development of novel compounds, which are now ready to move into clinical practice. This article summarizes the recent data on the development and use of compounds either inhibiting inflammatory cytokines or enhancing the activity of counter-regulatory cytokines in patients with UC and murine models of UC.Questo articolo è pubblicato sotto una Licenza Licenza Creative Commons
